Comparative Uptake Patterns of Radioactive Iodine and [18F]-Fluorodeoxyglucose (FDG) in Metastatic Differentiated Thyroid Cancers.
1/5 보강
Metastatic differentiated thyroid cancer (DTC) represents a molecularly heterogeneous group of cancers with varying radioactive iodine (RAI) and [F]-fluorodeoxyglucose (FDG) uptake patterns potentiall
- 표본수 (n) 46
APA
Diwanji D, Carrodeguas E, et al. (2024). Comparative Uptake Patterns of Radioactive Iodine and [18F]-Fluorodeoxyglucose (FDG) in Metastatic Differentiated Thyroid Cancers.. Journal of clinical medicine, 13(13). https://doi.org/10.3390/jcm13133963
MLA
Diwanji D, et al.. "Comparative Uptake Patterns of Radioactive Iodine and [18F]-Fluorodeoxyglucose (FDG) in Metastatic Differentiated Thyroid Cancers.." Journal of clinical medicine, vol. 13, no. 13, 2024.
PMID
38999527 ↗
Abstract 한글 요약
Metastatic differentiated thyroid cancer (DTC) represents a molecularly heterogeneous group of cancers with varying radioactive iodine (RAI) and [F]-fluorodeoxyglucose (FDG) uptake patterns potentially correlated with the degree of de-differentiation through the so-called "flip-flop" phenomenon. However, it is unknown if RAI and FDG uptake patterns correlate with molecular status or metastatic site. A retrospective analysis of metastatic DTC patients (n = 46) with radioactive 131-iodine whole body scan (WBS) and FDG-PET imaging between 2008 and 2022 was performed. The inclusion criteria included accessible FDG-PET and WBS studies within 1 year of each other. Studies were interpreted by two blinded radiologists for iodine or FDG uptake in extrathyroidal sites including lungs, lymph nodes, and bone. Cases were stratified by V600E mutation status, histology, and a combination of tumor genotype and histology. The data were analyzed by McNemar's Chi-square test. Lung metastasis FDG uptake was significantly more common than iodine uptake (WBS: 52%, FDG: 84%, = 0.04), but no significant differences were found for lymph or bone metastases. Lung metastasis FDG uptake was significantly more prevalent in the papillary pattern sub-cohort (WBS: 37%, FDG: 89%, = 0.02) than the follicular pattern sub-cohort (WBS: 75%, FDG: 75%, = 1.00). Similarly, V600E+ tumors with lung metastases also demonstrated a preponderance of FDG uptake (WBS: 29%, FDG: 93%, = 0.02) than V600E- tumors (WBS: 83%, FDG: 83%, = 1.00) with lung metastases. Papillary histology featured higher FDG uptake in lung metastasis (WBS: 39%, FDG: 89%, = 0.03) compared with follicular histology (WBS: 69%, FDG: 77%, = 1.00). Patients with papillary pattern disease, V600E+ mutation, or papillary histology had reduced agreement between both modalities in uptake at all metastatic sites compared with those with follicular pattern disease, V600E- mutation, or follicular histology. Low agreement in lymph node uptake was observed in all patients irrespective of molecular status or histology. The pattern of FDG-PET and radioiodine uptake is dependent on molecular status and metastatic site, with those with papillary histology or V600E+ mutation featuring increased FDG uptake in distant metastasis. Further study with an expanded cohort may identify which patients may benefit from specific imaging modalities to recognize and surveil metastases.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Associations between cumulative family environmental stress exposures and hair cortisol concentrations among 2.5- and 5-year-olds with different social competences.
- Temporal trends in second primary malignancies among long-term survivors of multiple myeloma across treatment eras: a population-based analysis of the SEER database.
- Automated RECOMIA AI-based total metabolic tumor volume in lymphoma - a retrospective study.
- Head-to-head comparison between F-FDG and F-PSMA-1007 PET/CT in diagnosing recurrent and metastatic prostate cancer.
- Preclinical and first-in-human evaluation of novel androgen receptor-targeted PET imaging in prostate cancer.